June 26, 2018
Video
Folate receptor alpha was a promising biomarker when it came to treatment with mirvetuximab soravtansine.
FDA Approves Initiation of a New Trial in Recurrent Glioblastoma
The Benefit of Clinical Trial Enrollment for Patients With Cancer
Addressing Gaps, Challenges and Disparities in AYA Cancer Care
Unexpected Challenges 11 Years After Breast Cancer